Citigroup Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its price objective dropped by investment analysts at Citigroup from $145.00 to $112.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target indicates a potential upside of 45.02% from the stock’s current price.

A number of other equities research analysts have also weighed in on the company. JPMorgan Chase & Co. dropped their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. UBS Group dropped their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Finally, William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average target price of $134.75.

Zoetis Stock Up 4.1%

NYSE ZTS traded up $3.01 on Monday, hitting $77.23. The stock had a trading volume of 4,952,899 shares, compared to its average volume of 5,050,831. The business’s fifty day moving average price is $112.28 and its 200 day moving average price is $120.76. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis has a 52-week low of $72.38 and a 52-week high of $172.23. The stock has a market cap of $32.38 billion, a price-to-earnings ratio of 12.83, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm posted $1.48 earnings per share. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts anticipate that Zoetis will post 6.91 earnings per share for the current year.

Insider Activity at Zoetis

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 11,650 shares of company stock worth $886,384 over the last quarter. Insiders own 0.22% of the company’s stock.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently modified their holdings of ZTS. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the 4th quarter valued at about $25,000. Prosperity Bancshares Inc purchased a new stake in Zoetis in the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $28,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $30,000. Finally, Root Financial Partners LLC grew its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.